Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke

NCT02530307 is registered in ClinicalTrials.gov with Dart NeuroScience, LLC as lead sponsor.

NCT NCT02530307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02530307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke
Lead sponsor
Dart NeuroScience, LLC
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2016
Completion date
December 31, 2017
Enrollment
61 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke